安罗替尼治疗晚期软组织肉瘤的真实世界研究  

Real world study of anlotinib in the treatment of advanced soft tissue sarcoma

作　　者：袁思越 叶挺 张洁莹 周瑀涵 陈静[1] Yuan Siyue;Ye Ting;Zhang Jieying;Zhou Yuhan;Chen Jing(Cancer Center,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,China)

机构地区：[1]华中科技大学同济医学院附属协和医院肿瘤中心,武汉430022

出　　处：《中华转移性肿瘤杂志》2021年第2期87-93,共7页Chinese Journal of Metastatic Cancer

摘　　要：目的研究真实世界中安罗替尼治疗晚期软组织肉瘤(STS)的疗效与安全性。方法收集本中心2018—2020年间接受安罗替尼治疗的晚期STS患者资料,回顾性分析治疗有效率、无进展生存、总生存和不良反应。结果共纳入患者43例,病理亚型14种,单药治疗27例,联合治疗16例;一线、二线、三线及以上治疗分别为11、16、16例。总客观缓解率(ORR)为16%,疾病控制率(DCR)为67%,中位无进展生存期(mPFS)为8.0个月,中位总生存期(mOS)为29.4个月。腺泡状STS和平滑肌肉瘤疗效最好,ORR分别为83%和10%,DCR均为100%,mPFS为26.5个月和13.8个月。一线、二线、三线及以上治疗的ORR分别为36%、13%、6%;DCR分别为82%、81%、44%;mPFS分别为26.6、10.4、1.3个月。不良反应发生率较高的为高血压、乏力、甲状腺功能减退和胆固醇升高,多为1~2级。结论安罗替尼对晚期STS有一定疗效,腺泡状STS和平滑肌肉瘤疗效最好,前线治疗的疗效可能优于后线。安罗替尼单独使用和联合使用均具有良好安全性。Objective To study the efficacy and safety of anlotinib in the treatment of advanced soft tissue sarcoma in the real world.Methods The data of patients with advanced soft tissue sarcoma treated with anlotinib in our center from June 2018 to December 2020 were collected.The response rate,median progression-free survival time,overall survival and adverse reactions were retrospectively analyzed.Results A total of 43 patients with 14 pathological subtypes were enrolled in this study,27 patients were treated with anlotinib alone and 16 patients were treated with anlotinib combined therapy.The first-line,second-line and third-line or above treatment were 11,16 and 16 patients respectively.The overall objective response rate(ORR)was 16.3%and the overall disease control rate(DCR)was 67.4%.The median progression-free survival(mPFS)was 8.0 months and the median overall survival(mOS)was 29.4 months.Alveolar soft tissue sarcoma and leiomyosarcoma had the best curative effect,with ORR of 83.3%and 10.0%respectively,both with DCR of 100.0%,and mPFS of 26.5 months and 13.8 months.The ORR for the first-line、second-line and third-line or above treatment were 36.4%,12.5%and 6.3%respectively;the DCR were 81.9%,81.3%and 43.8%;the mPFS were 26.6、10.4 and 1.3 months.The higher incidence of adverse reactions were hypertension,fatigue,hypothyroidism and elevated cholesterol,and most of them were grade 1~2.Conclusions Anlotinib had shown efficacy in the treatment of advanced soft tissue sarcoma,especially for alveolar soft part sarcoma and leiomyosarcoma.The efficacy of the front line was better than that of the posterior line.Both alone and combined use of arotinib have good safety.

关 键 词：安罗替尼 软组织肉瘤 靶向治疗 疗效 安全性 

分 类 号：R73[医药卫生—肿瘤]